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2Abstract
Background and Purpose:The pathophysiology of Type 2 diabetes differs markedly by 
ethnicity. A systematic review and meta-analysis was conducted to assess the impact of 
ethnicity on the glucose lowering efficacy of the newer oral agents, SGLT-2is, GLP-1RAs and 
DPP-4is, using evidence from randomized clinical trials (RCTs). 
Data Sources:A literature search was conducted in PubMed of all randomized, placebo-
controlled trials of DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1RA. The search strategy 
was developed based on medical subject sub-headings (MeSH) terms and keywords.
Study selection : 64 studies qualified for meta-analysis after full-text review based on pre-
defined inclusion and exclusion criteria. RCTs  with at least 50 patients in each arm; >70% of 
population from Asian or White group; duration>=24 weeks; published up to March 2019 were 
selected for systematic review and meta-analysis.
Data extraction:Data extraction was done for aggregated study-level data , by two independent 
researchers. Absolute changes in HbA1c (%) from baseline to 24 weeks between the drug and 
placebo was considered as the primary endpoint of the study.
Data synthesis: Change in HbA1c was evaluated by computing mean differences (MDs) and 
95% confidence intervals (CI) between treatment and placebo arms. 
Limitations:  Study is based on summarized data and could not be separated based on East 
Asians and South Asians.
Conclusion : The glucose lowering efficacy of SGLT-2i, and to a lesser extent DPP-4i, was 
greater in studies of predominantly Asian ethnicity compared to studies of predominantly white 
ethnicity.  There was no difference seen by ethnicity for GLP-1RA.
PROSPERO registration [CRD42019133587].
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4INTRODUCTION
Type 2 diabetes presents a global threat to health. According to the International Diabetes 
Federation (IDF) 2017 report China has the highest number of people (114.4 million) with 
diabetes in the age group 20-79. This is closely followed by India (72.9 million) which is 
projected to have the highest number of people with diabetes by 2045 (134.3 million)1. Yet 
most studies of diabetes are undertaken in western populations2 and treatment guidelines do 
not take ethnicity into account.  The latest  consensus report by the American Diabetes 
Association (ADA) and the European Association for the Study of Diabetes (EASD) 
recommends the use of relatively newer drugs such as SGLT-2 inhibitors, GLP-1RA, and DPP-
4 inhibitors in combination with metformin and lifestyle adjustments3, unless cost is an issue.  
Nearly half of the subjects with diabetes fail to achieve the recommended treatment target and 
the reasons for this are multifactorial4,5.
The pathophysiology and metabolic phenotype of type 2 diabetes differs markedly by ethnicity.  
For example, South east Asians and South Asians develop type 2 diabetes at younger age and 
lower BMI than whites6,7,8; and beta-cell deficiency has been reported to be a feature of Asian 
diabetes6.  These pathophysiological differences may impact on treatment efficacy as most 
diabetes therapies largely target the underlying pathophysiological defects.  
Even though a large number of studies have been carried out to measure safety and efficacy of 
anti-diabetic agents, only a few report on these measures in those of different ethnicity. 
Previous meta-analysis on DPP-4 inhibitors (reported in 2013) and GLP-1RAs (reported in 
2014) based on ethnicity have reported that Asians responded better than non-Asians9,10,11.  
These studies defined a population as Asian if it was >50% Asian and White if the population 
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5was <50% Asian; and included studies of short duration. There are no previous studies 
reporting efficacy of SGLT-2 inhibitors based on ethnicity. Thus, we performed a systematic 
review and meta-analysis to comprehensively assess the impact of ethnicity on the glucose 
lowering efficacy of relatively newer anti-diabetic agents; SGLT-2 inhibitors, GLP-1RAs and 
DPP-4 inhibitors using published evidence from randomized clinical trials reported up to 31 
March 2019.
METHODS
Participants of three groups were considered for the study.
a) Receiving DPP-4 inhibitor alone or in combination with other drugs
b) Receiving SGLT-2 inhibitor alone or in combination with other drugs
c) Receiving GLP-1RA alone or in combination with other drugs
Data Sources and Searches
The meta-analysis was carried out using methods proposed in the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis statement12. A literature search was conducted in 
PubMed for studies published up to March 31, 2019, by two independent investigators (SG, 
AYD) of all randomized, placebo-controlled trials of DPP-4 inhibitors, SGLT-2 inhibitors and 
GLP-1RA. The search strategy was developed based on medical subject sub-headings (MeSH) 
terms and keywords. The search algorithm is presented in detail in the supplementary 
document. 
Study selection 
Page 5 of 66
CONFIDENTIAL-For Peer Review Only
Diabetes Care
6A title-based search was conducted followed by abstract screening. A full paper search of 
potentially eligible studies was also performed based on the pre-defined inclusion and 
exclusion criteria. Any discrepancies in selection was resolved by a third researcher (ERP). 
Inclusion criteria 
1. Randomized Controlled Trial (RCT) on adult, non-pregnant participants aged 18 or 
older with type 2 diabetes. 
2. The efficacy of the drug was the primary outcome of the study.
3. Study reported the effect of drug versus placebo on the HbA1c in participants who were 
either drug naïve or on background therapy.
4. Study reported outcome by ethnicity and one ethnic group constituted at least 70% or 
more participants.
5. Studies were filtered on the basis of humans, clinical trials and age 19+. 
6. Study written in English.
Exclusion criteria 
1. Study duration was less than 24 weeks or more than 52 weeks.
2. The study had less than 50 participants in each study arm.
3. Participants were on insulin as background therapy.
4. Studies that were extensions of previous RCTs.
5. Studies that included participants under inpatients care.
6. Non RCT studies and reviews.
Data extraction
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7Data extraction was done for aggregated study-level data , by two independent researchers. 
Absolute changes in HbA1c (%) from baseline to 24 weeks between the drug and placebo was 
considered as the primary endpoint of the study. In case data was not available for 24 weeks, 
52 weeks was considered. Studies with duration >52 weeks were excluded as these were open 
label extensions. A standardized pre-piloted form was used to extract data from the included 
studies for assessment of study quality and synthesis. Extracted information included: author, 
year of publication, sample sizes, participant demographics and baseline characteristics, 
interventions and HbA1c outcomes of the lowest dose(in case multiple doses were reported 
and placebo). Further, the studies were classified by their ethnicities provided percentage of 
participants in a particular ethnic group was more than 70%. A hierarchical approach was 
adopted to decide the relevance of studies based on title, abstract and full manuscript. If a study 
had more than two relevant arms, each arm was treated separately. Selection process of relevant 
studies retrieved from databases was shown in a PRISMA compliant flowchart.
We have used the classification of ‘Asian’ or ‘White’ of each study as it was reported in the 
manuscript. Where studies were conducted in relatively homogenous populations in Asian 
countries (eg Korea, China, Japan and Taiwan), we have considered the participants to be in 
the ‘Asian’ group. We have also followed the definitions of ‘East Asians’ (China, Japan, 
Mongolia, North Korea and South Korea) and ‘South Asians’(Afganistan, Bangladesh, Bhutan, 
India, Maldives, Mauritius, Nepal, Pakistan, and Sri Lanka) from previous reports13,14.
 To ensure more robust ethnicity specific outcomes we required >70% of the population to be 
Asian or White for the study to be allocated to that ethnic group; and to ensure more robust 
treatment effects we limited our studies to those where the study duration was >=24 weeks and 
where there were more than 50 participants in the intervention and comparison arms.
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The quality of eligible studies were evaluated by two independent researchers using the 
Cochrane Collaboration’s risk of bias tool15 for assessing the design, execution and reporting 
of the included RCTs. Risk of bias was assessed in random sequence generation and allocation 
concealment (selection bias), blinding of participants and personnel (performance bias), 
incomplete outcome data (attrition bias) and selective reporting (reporting bias). The risk of 
bias was classified as high, low or unclear. Funnel plot and Egger’s test was carried out to 
assess the publication bias of the overall studies for each drug.
Data synthesis and analysis
For each drug group, meta-analysis was performed with the combined data and stratified 
analysis by ethnic group using meta package in R Studio (version 1.0.153). Change in HbA1c 
was evaluated by computing mean differences (MDs) and 95% confidence intervals (CI) 
between treatment and placebo arms. The MDs were calculated as the change from baseline to 
end point. When standard deviation was not reported, it was estimated by the formula provided 
by the Cochrane Handbook for Systematic Reviews of Interventions16. Forest plots for White 
and Asian dominant groups were constructed using RStudio. Higgins I2 statistics was used to 
evaluate between study heterogeneity and classified as low (<25%), moderate (25-75%) or 
high (>75%)16. The Q statistic was used as a test of heterogeneity. τ2 was estimated by Der-
Simonian Laird Estimation Method17. A random effects model was used to estimate the pooled 
effect. Statistical significance was considered as p value<0.05. Tests for subgroup differences 
were carried out to check if there were any significant differences between ethnic groups. Meta-
regression analyses were performed to determine whether estimates of treatment effects were 
associated with prespecified clinical characteristics such as: age, duration of disease, 
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sensitivity analysis was conducted considering study duration from 12 weeks to 52 weeks for 
all the three drug groups, with all other criteria kept the same. 
This review is registered with PROSPERO[CRD42019133587].
RESULTS
DPP-4inhibitors
Search results and study characteristics: Initially, 1411 articles were identified from the 
database, 12 articles were identified from references of other articles, 26 articles were included 
in the meta-analysis. A total of 26 comparison pairs were retrieved which satisfied the selection 
criteria (Fig S1a). The total number of study participants were 8531 of which 4728 were 
randomised to treatment arms and 3803 to the placebo arms. The White dominant group (17 
studies) consisted of 5185 participants of which 3051 participants were randomised in the 
treatment group and 2134 participants in the placebo group. The Asian dominant group (9 
studies) consisted of 3346 participants of which 1677 participants were randomised in the 
treatment group and 1669 participants in the placebo group (Fig 1). The summary of included 
studies are shown in Supplementary Table S1.
Quality of included studies and publication bias assessments: For the adequacy of sequence 
generation, 13 studies were categorised as unclear and 13 studies were categorised as low risk. 
All the included studies achieved the double blinding for the participants and the personnel. 
The allocation concealment was unclear in 16 studies and 10 studies were at low risk. There 
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was no particular indication of incomplete data, selective reporting or other biases in any of 
the included studies (Table S1a and Fig S1b). The Egger’s Test and funnel plot suggested that 
there was no asymmetric pattern and no particular concern regarding publication bias 
(p=0.626) (Fig S1c and S1d).
Efficacy Outcomes: HbA1c data were pooled from the 26 comparison pairs from 26 studies. 
Overall, the difference between the treatment and placebo groups was -0.53[CI -0.62,-0.44 ; 
I2=78%]favouring treatment (Fig 1). In the White dominant group, the difference between 
treatment and placebo groups was -0.49[CI  -0.59,-0.38 ; I2=74%] favouring treatment. In the 
Asian dominant group the difference between treatment and comparison group was -0.62[CI -
0.80,-0.45 ; I2=84%] favouring treatment (Fig 1). The test for sub-group differences (random 
effects model) showed no difference (p=0.1919) between the two groups (Table S2a).
Exploratory Analysis: The median (range) duration of diabetes was 6.1 (2.9-12.2) in the White 
dominant group and 6.4 (0.97-8.15) for the Asian dominant group. The median(range) HbA1c 
at baseline was 8.065(7.8-8.6) in the White dominant group and 8.5(7.9-9.4) in the Asian 
dominant group. The median (range) BMI at baseline was 31.7 (28.1-32.90) in the White 
dominant group and 25.9(25.30-27.90) in the Asian dominant group.
Meta-regression: The univariate meta-regression analysis showed age (p=0.33), percentage of 
white participants (p=0.12), HbA1c at baseline (p=0.98), duration of diabetes (p=0.22), 
percentage of men (p=0.60), BMI at baseline (p=0.38) were not associated with the change in 
HbA1c from baseline (Table S3 and Fig S4).
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Sensitivity Analysis: Here we included additional studies with a shorter duration (from 12 
weeks to 52 weeks).  Out of the 1411 articles identified from the database, an additional 7 
studies were identified, totalling 33 studies included in the sensitivity analysis. Overall, the 
difference between the treatment group and comparison group was -0.59[CI -0.70, -0.48; 
I2=94%] favouring treatment (Fig S1e). In the White dominant group, the difference between 
treatment group and comparison group was -0.49[CI -0.59,-0.39 ; I2=73%] favouring 
treatment. In the Asian dominant group the difference between treatment and comparison 
group was -0.73[CI -0.88,-0.57 ; I2=94%] favouring treatment (Fig S1e). Test for sub-group 
differences (random effects model) showed a greater response in the Asians compared to the 
White predominant group (p=0.0098) (Table S2b).
SGLT-2inhibitors
Search results and study characteristics:  16 articles were included in the study from the 555 
articles that were identified from the database(Fig S2a). The total number of study participants 
were 4189 of which 2178 were randomised in the treatment group and 2011 were from placebo 
group. The White dominant group (9 studies) consisted of 3015 participants of which 1515 
participants were randomised in the treatment group and 1500 participants in the placebo 
group. The Asian dominant group (7 studies) consisted of 1174 participants of which 663 
participants were randomised in the treatment group and 511 participants in the placebo group. 
The summary of included studies is shown in Supplementary Table 1.                                                   
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Quality of included studies and publication bias assessments: All the studies were double blind 
for the participants and personnel. For the adequacy of sequence generation, 5 studies were 
categorised as unclear, 8 studies were categorised as low risk and 3 studies were categorised 
as high risk. The allocation concealment was unclear in 4 studies, 11 studies were at low risk 
and 2 studies were at high risk. There was no particular indication of incomplete data, selective 
reporting or other biases in any of the included studies (Table S1b and Fig S2b). The Egger’s 
Test and funnel plot suggested that there was no asymmetric pattern and no particular concern 
regarding a publication bias (Fig S2b and S2c). 
Efficacy Outcomes: HbA1c data was pooled from the 16 comparison pairs from 16 studies. 
Overall, the difference between the treatment group and comparison group was -0.79[CI -0.91, 
-0.66; I2=80%] favouring treatment (Fig 2). In the White dominant group, the difference 
between treatment group and comparison group was -0.64[CI -0.74, -0.53; I2=44%] favouring 
treatment. In the Asian dominant group, the difference between treatment and comparison 
group was -0.96[CI -1.10, -0.82; I2=66%] favouring treatment. Test for sub-group differences 
(random effects model) showed a significant difference (p=0.0003) between the two groups 
(Table S2a).
Exploratory Analysis: The median(range) duration of diabetes was 8.3(5.64-12.3) in the White 
dominant group and 7.49(4.72-11.6) for the Asian dominant group. The median(range) HbA1c 
at baseline was 8.17(7.8-9.3) in the White dominant group and 8.18(7.9-8.45) in the Asian 
dominant group. The median(range) BMI at baseline was 31.9(31.2-33.3) in the White 
dominant group and 25.59(25.07-26.0) among the Asian dominant group.
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Meta-regression: The univariate meta-regression analysis showed percentage of white 
participants (p<0.01), BMI at baseline (p=0.01) are associated with the change in HbA1c from 
baseline. On the other hand, age (p=0.38), HbA1c at baseline (p=0.80), duration of diabetes 
(p=0.85), and percentage of men (p=0.1) were not associated with the change in HbA1c from 
baseline (Table S3 and Fig S5).
Sensitivity Analysis: Including 5 additional studies between 12 and 24 week duration, HbA1c 
data were pooled from 21 comparison pairs from 21 studies. Overall, the difference between 
the treatment group and comparison group was -0.70[CI -0.82, -0.58; I2=84%] favouring 
treatment (Fig S2e). In the White dominant group, the difference between treatment group and 
comparison group was -0.57[CI -0.69, -0.44; I2=69%] favouring treatment. In the Asian 
dominant group the difference between treatment and comparison group was -0.85[CI -1.03, -
0.66; I2=87%] favouring treatment (Fig S2e). Test for sub-group differences (random effects 
model) showed a difference (p=0.0182) between the two groups (Table S2b).
GLP-1RA
Search results and study characteristics:  1481 articles were identified from the database and 
4 articles were identified from references of other articles from which 22 articles were included 
in the meta-analysis (Fig S3a). A total of 23 comparison pairs were retrieved which satisfied 
the selection criteria. The total number of study participants were 6559 of which 3608 were 
randomised in the treatment group and 2951 were from placebo group. The White dominant 
group (19 studies, 20 arms) consisted of 5682 participants of which 3608 participants were 
randomised in the treatment group and 2951 participants in the placebo group. The Asian 
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dominant group (3 studies) consisted of 877 participants of which 438 participants were 
randomised in the treatment group and 439 participants in the placebo group. The summary of 
included studies are shown in Supplementary Table S1.
Quality of included studies and publication bias assessments: All the 22 of the studies achieved 
the double blindness for the participants and the personnel. For the adequacy of sequence 
generation, 14 studies were categorised as unclear and 8 studies were categorised as low risk. 
The allocation concealment was unclear in 6 studies and 16 studies were at low risk. There was 
no particular indication of incomplete data, selective reporting or other biases in any of the 
included studies (Table S1c and Fig S3b). The Egger’s Test and funnel plot suggested that 
there was no asymmetric pattern and no particular concern regarding a publication bias (Fig 
S3c and S3d). 
Efficacy Outcomes: HbA1c data were pooled from the 23 comparison pairs from 22 studies. 
Overall, the difference between the treatment group and comparison group was -0.78[CI -0.88,-
0.69 ; I2=79%] favouring treatment (Fig 3). In White dominant group, the difference between 
treatment group and comparison group was -0.79[CI  -0.89,-0.69 ; I2=77% ] favouring 
treatment. In the Asian dominant group the difference between treatment and comparison 
group was -0.76[CI  -1.19,-0.33 ; I2=90%] favouring treatment (Fig 3). Test for sub-group 
differences (random effects model) showed no statistically significant difference (p=0.8957) 
between the two groups(Table S2a).
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Exploratory Analysis: The median (range) duration of diabetes was 7.6(2.8-13.6) in the White 
dominant group and 9.3(4.0-13.7) for the Asian dominant group. The median(range) HbA1c at 
baseline was 8.1(7.5-9.3) in the White dominant group and 8.54(7.95-8.6) in the Asian 
dominant group. The median(range) BMI at baseline was 32.94(29.9-36.9) in the White 
dominant group and 25.4(25.3-26.8).
Meta-regression : The univariate meta-regression analysis showed age (p=0.98), percentage 
of white participants (p=0.99), HbA1c at baseline (p=0.99), duration of diabetes (p=0.54), 
percentage of men (p=0.59), BMI at baseline (p=0.94) were not significantly associated with 
the change in HbA1c from baseline (Table S3 and Fig S6).
Sensitivity Analysis : Including 4 additional studies that were identified between 12 and 24 
week duration, HbA1c data were pooled from 27 comparison pairs from 26 studies. Overall, 
the difference between the treatment group and comparison group was -0.79[CI -0.88,-0.70 ; 
I2=76%] favouring treatment (Fig S3e). In the White dominant group, the difference between 
treatment group and comparison group was -0.79[CI  -0.89,-0.70 ; I2=75.1%] favouring 
treatment. In the Asian dominant group the difference between treatment and comparison 
group was -0.79[CI  -1.03,-0.54 ; I2=82%] favouring treatment (Fig S3e ). Test for sub-group 
differences (random effects model) showed no statistically significant difference (p=0.9657) 
between the two groups (Table S2b).
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The current systematic review and meta-analysis focuses on the HbA1c-lowering efficacy of 
DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1RAs in ethnically White and Asian 
participants. Compared to Whites, Asians respond better to SGLT-2is. Even though the 
primary analysis of DPP-4 inhibitors showed no difference in response to DPP-4 inhibitors 
between the two groups, the sensitivity analysis including shorter duration studies did show 
that Asians respond better to DPP-4 inhibitors than Whites in keeping with previous reports. 
No difference was found in the response to GLP-1RAs between Asians and Whites. 
This is the first meta-analysis which reports glycemic response to SGLT-2 inhibitors by 
ethnicity. Our results showed that the Asians respond better to SGLT-2 inhibitors as compared 
to the White dominant group. In the meta-regression, the percentage of White in the population 
and BMI at baseline were associated with the HbA1c reduction, whereas baseline HbA1c was 
not correlated. A recent meta-analysis showed that efficacy and safety of SGLT-2 inhibitors 
were favourable in East Asian patients with Type 2 diabetes13. It is interesting to know that 
SGLT-2 inhibitors also show greater, albeit non-significant,  cardiovascular risk reduction  in 
Asians compared to other ethnic groups18.
Although, no significant difference was found between the two groups for DPP-4 inhibitors, 
the reduction in HbA1c levels at study endpoint was greater for the Asian dominant studies 
(between group difference p=0.1919). However, our sensitivity analysis that included studies 
of shorter duration (from 12 weeks) did show a -0.11% significantly greater reduction in 
HbA1c in the predominantly Asian group compared to the predominantly white population.  A 
previous meta-analysis by Kim et al reported DPP-4 inhibitors showed greater HbA1c lowering 
effect in Asian-dominant studies than the non-Asian dominant studies (between group 
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difference : -0.18%, p=0.006)9. In another review, Ito et. al hypothesized that DPP-4 inhibitors 
had greater efficacy among East-Asian participants than their White counterparts due to the 
different pathophysiology of type 2 diabetes between the two ethnic groups19. Interestingly 
these two meta-analyses also included studies of 12 weeks or longer. Finally, in an individual 
level analysis of TECOS, Davis et al showed that the greatest initial reduction of HbA1c was 
observed in East Asians on Sitagliptin.20 It is not clear why our primary analysis based upon 
studies of at least 24 weeks showed a smaller difference between ethnic groups; there was no 
obvious difference or bias introduced in the shorter duration studies but the results would 
suggest the difference seen at 12 weeks does not persist to 24 weeks or longer.  Previous studies 
on sitagliptin and vildagliptin have reported that the clinical pharmacokinetic characteristics of 
DPP-4 inhibitors were not different among Asian, Black, Hispanics and Whites, suggesting 
that differences in response are more likely to reflect phenotypic or pathophysiological 
differences21,22.  Lower BMI has been reported to be associated with a better glycemic 
response23, yet in  the present study, the meta-regression showed no correlation between age, 
BMI at baseline, percentage of White, HbA1c at baseline, duration of diabetes, percentage of 
men and HbA1c reduction. This meta-regression suggests that the greater HbA1c reduction 
seen in Asians in our meta-analysis is not driven by the higher HBA1c at recruitment in the 
Asian populations.  There may, however, be other differences between ethnic groups that are 
not captured in the recorded baseline characteristics, such as adherence, that  could have 
contributed to differences in results.  The use of other glucose lowering agents in the trials were 
quite similar between Asian and White dominant studies and hence are unlikely to explain 
ethnic differences in treatment efficacy (Table S4). 
In the present meta-analysis, no difference in efficacy was found between the White and Asian 
dominant groups (p=0.8957) among the studies of GLP-1RA.  In a previous meta-analysis, 
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conducted on GLP 1 analogues by Kim et al, it was found that HbA1c reduction from baseline 
was greater in Asian dominant groups than in non-Asian dominant groups10.  The fact that we 
show no evidence of difference in response between Asians and Whites is at odds with this 
previous report.  However, unlike for DPP-4 inhibitors, for GLP-1RA, including shorter 
duration studies in our analysis, similar to that of Kim et al, did not make any difference to the 
estimate of efficacy difference. Even though our study had only three Asian studies included 
these differed from that of the three Asian studies included by Kim et al in their meta-analysis.  
Thus our lack of replication of the previous meta-analysis may reflect this small number of 
studies and heterogeneity between studies in the Asian population.
The only remaining differences were that in our study design, to ensure separation between 
studies reporting efficacy in Whites vs Asians we defined a population cut off of 70%, whereas 
Kim et al. used a 50% cut off, and we only included studies that have 50 patients per treatment 
arm.  
There are some limitations to this study. First, this systematic review and meta-analysis is based 
on summarized data of RCT studies. Further investigation of individual level trial data based 
on ethnicity is required to confirm the reported differences for SGLT2i and DPP4i.  Second, 
due to lack of enough studies that satisfied our inclusion and exclusion criteria, studies could 
not be separated based on South Asians and East Asians. It is known from previous reports that 
South Asians and East Asians are ethnically heterogeneous and this demands for more studies 
to be conducted in the South Asian region14.
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In conclusion, the glucose lowering efficacy of SGLT-2 inhibitors and DPP-4 inhibitors was 
higher in Asian dominant group as compared to the White dominant group but not for and 
GLP-1 analogues.  Our data suggest that, if our results are replicated by individual-level patient 
analyses from clinical trials, ethnicity should be incorporated into the treatment guidelines.  
Further studies would also be warranted as to the physiological or pharmacological basis of 
these differences, given the reported beta-cell deficiency and visceral adiposity in Asians.  
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Fig 1: Forest plot for White and Asian dominant groups for DPP-4 inhibitors 
Fig 2 : Forest plot for White and Asian dominant groups for SGLT-2 inhibitors 
Fig 3 : Forest plot for White and Asian dominant groups for GLP-1RA
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Heterogeneity: I2 = 78%, τ2 = 0.0390, p < 0.01







Heterogeneity: I2 = 84%, τ2 = 0.0586, p < 0.01
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Heterogeneity: I2 = 80%, τ2 = 0.0489, p < 0.01







Heterogeneity: I2 = 66%, τ2 = 0.0223, p < 0.01
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Heterogeneity: I2 = 79%, τ2 = 0.0434, p < 0.01







Heterogeneity: I2 = 77%, τ2 = 0.0377, p < 0.01
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White Duration of Treatment
 (%) (weeks)
Dou J1 2017 Asian 0 24
Wang W2 2016 Asian 10.5 24
Yang W3 2014 Asian 0 24
Lukashevich V4 2013 Asian 21.5 24
Pan C5 2012 Asian 0 24
Pan CY6 2011 Asian 0 24
Yang W7 2011 Asian 0 24
Yang8 2012 Asian 0 24
Kadowaki9 2017 Asian 0 24
Gantz I9 2017 White 82.4 24
Tinahones FJ10 2016 White 98.4 24
Matthaei S11 2015 White 88.9 24
Barnett AH12 2013 White 96.9 24
Strain WD13 2013 White 97.1 24
Derosa G14 2012 White 100 24
Taskinen MR15 2010 White 75 24
Rosenstock J16 2009 White 87.3 24
DeFronzo RA17 2009 White 79.7 24
Nauck MA18 2009 White 80 26
Garber AJ19 2007 White 83.9 24
Bosi E20 2007 White 74.1 24
Rosenstock J21 2006 White 72.6 24
Gomis R22 2011 White 74.5 24
Bergenstal23 2012 White 76 24
Pratley_Pio24 2009 White 72.6 26
Pratley_SU25 2009 White 100 26
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Mean Age Baseline HbA1c level Duration of diabetes Men BMI
(years) (%) (Years) (%) (kg/m2)
49.5 9.4 0.97 64.8 26.7
56.5 8.9 7.4 50.8 25.9
58.3 8.6 6.9 55.2 24.8
55.3 8.7 7.1 50.6 27.9
54.2 8.09 4.92 50 26.01
51.2 8.1 0.8 56.3 25.9
53.8 7.9 5.1 48.1 26.3
54.1 8.5 6.4 47 25.3
55.9 7.98 8.15 83.1 25.53
38.8 7.9 2.9 65.7 32.9
56.6 8.04 NR 56.6 31.3
54.7 7.97 8.1 47.7 31.4
74.9 7.8 NR 71.6 29.6
75.1 7.9 12.2 52.5 29.1
55.9 8.1 5.8 46.1 28.1
56.5 8.09 NR 57 30.05
53.27 7.9 3.1 45.9 31.9
54.7 8.1 6.7 43.2 31.7
55 7.9 6 47.4 32
54 8.6 4.7 54.8 32.6
54.3 8.4 6.8 57.3 32.1
55.6 8.1 6.1 53.1 32
57.7 8.6 NR 58.7 28.7
55.5 7.94 6 59 32.4
55.5 8.1 7.7 55.3 32.3
56.5 NR 7.6 50 30
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Background Therapy Drug Participants (n) Comparator Participants (n)
Metformin Saxagliptin 210 Placebo 207
Sitagliptin 185 Placebo 180
SU Vildagliptin 143 Placebo 136
Metformin+SU Vildagliptin 158 Placebo 160
Vildagliptin 146 Placebo 144
Saxagliptin 284 Placebo 284
Metformin Saxagliptin 283 Placebo 287
Metformin Sitagliptin 191 Placebo 194
Canagliflozin Tenegliptin 77 Placebo 77
Omarigliptin 102 Placebo 101
Empa+ Met Linagliptin 122 Placebo 125
Dapa+Met Saxagliptin 153 Placebo 162
Linagliptin 160 Placebo 78
Vildagliptin 137 Placebo 137
Metformin Sitagliptin 91 Placebo 87
Metformin Linagliptin 513 Placebo 175
Saxagliptin 102 Placebo 95
Metformin Saxagliptin 186 Placebo 175
Metformin Alogliptin 213 Placebo 104
Pioglitazone Vildagliptin 146 Placebo 158
Vildagliptin 177 Placebo 182
Pioglitazone Sitalgliptin 175 Placebo 178
Pioglitazone Linagliptin 252 Placebo 128
Sitagliptin 177 Placebo 90
Pioglitazone Alogliptin 197 Placebo 97
SU Alogliptin 148 Placebo 62
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White Duration of TreatmentMean AgeBaseline HbA1c level
 (%) (weeks) (years) (%)
Han KA26 2018 Asian 0 24 57.62 7.9
Kawamori R27 2018 Asian 0 24 60 8.27
Kadowaki T28 2017 Asian 0 24 58.4 8.18
Kashiwagi A29 2014 Asian 0 24 56.2 8.25
Kaku K30 2014 Asian 0 24 58.6 8.45
Inagaki N31 2014 Asian 0 24 58.4 7.98
Seino Y32 2014 Asian 0 24 58.9 8.14
Mathieu C33 2016 White 93.8 52 55.2 8.24
Rodbard HW34 2016 White 74.8 26 57.4 8.5
Mathieu C35 2015 White 93.8 24 55.2 8.24
Matthaei S36 2015 White 96.3 24 61.1 8.08
Jabbour SA37 2013 White 72.2 24 54.8 7.9
Wilding JP38 2013 White 84.1 26 57.4 8.1
Rosenstock J39 2012 White 72.3 24 53.2 8.4
Bode B40 2013 White 80.5 26 64.3 7.8
Jabbour SA41 2018 White 83.3 28 53.8 9.3
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(Years) (%) (kg/m2) (n)
11.6 50.7 25.5 Ifragliflozin 73 Placebo
9 78 26 Linagliptin Empagliflozin 182 Placebo
8.34 77.1 25.53 Tenegliptin Canagliflozin 70 Placebo
7.49 58.9 25.96 Ipragliflozin 112 Placebo
6.3 66.7 25.07 Tofogliflozin 57 Placebo
4.72 65.6 25.59 Canagliflozin 90 Placebo
6.5 75.9 25.98 Luseogliflozin 79 Placebo
7.2 43.7 31.2 Saxa+Met Dapagliflozin 160 Placebo
9.8 61.7 32.3 Canagliflozin 107 Placebo
7.2 43.7 31.2 Saxa+Met Dapagliflozin 158 Placebo
9.3 42.6 31.9 Dapagliflozin 108 Placebo
5.7 57 Dapagliflozin 223 Placebo
9 48.4 33.3 Canagliflozin 157 Placebo
5.64 55.3 Dapagliflozin 141 Placebo
12.3 51.5 31.4 Canagliflozin 241 Placebo
7.6 51.1 32 Exenatide Dapagliflozin 228 Placebo
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White Duration of TreatmentMean AgeBaseline HbA1c level
 (%) (weeks) (years) (%)
Yu Pan C42 2014 Asian 0 24 54.5 7.95
Seino Y43 2012 Asian 0 24 58.7 8.54
Kaku K44 2010 Asian 0 24 59.1 8.6
Jabbour SA41 2018 White 83.3 28 53.8 9.3
Lingvay I45 2018 White 76.6 26 57.5 7.9
Ludvik B46 2018 White 89 24 56.17 8.04
Meneilly GS47 2017 White 72.7 24 74 8.1
Dungan KM48 2016 White 84.5 24 57.7 8.4
Nauck MA49 2015 White 84.2 52 53.6 8
Reusch J50 2014 White 72.7 52 55.2 8.1
Wysham C51 2014 White 74 26 56 8.1
Wysham C52 2014 White 76 26 55 8.1
Bolli GB53 2013 White 87.13 24 55.4 8
Derosa G54 2013 White 100 24 57.3 8.1
Pinget M55 2013 White 85 24 56 8.1
Derosa G56 2012 White 100 52 57.3 8.1
Zinman B57 2009 White 81 26 55 8.5
Nauck M58 2008 White 84 26 56 8.4
DeFronzo RA59 2005 White 77.3 30 53 8.3
Bergenstal60 2012 White 79 24 55.3 7.95
Henry61 2012 White 75 24 52.5 8.2
Raz62 2012 White 86 24 53.4 7.5
Hollander63 2013 White 92 24 53 7.54
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Duration of diabetes Men BMI
Background Therapy Drug Participants(n) Comparator
(Years)  (%) (kg/m2)
4 51.5 26.8 Lixisenatide 196 Placebo
13.7 44.8 25.4 Lixisenatide 154 Placebo
9.3 40 25.3 Liraglutide 88 Placebo
7.6 51.1 32 Dapagliflozin Exenatide 228 Placebo
6.5 51.6 32.3 Semaglutide 64 Placebo
9.21 54 32.87 Dulaglutide 142 Placebo
13.6 52.3 29.9 Lixisenatide 176 Placebo
7.8 43.5 30.9 Dulaglutide 239 Placebo
3.4 57.4 33.7 Albiglutide 101 Placebo
8 61.3 33.6 Albiglutide 150 Placebo
9 58 33 Dulaglutide 279 Placebo
9 57 34 Exenatide 276 Placebo
5.8 44 33 Lixisenatide 161 Placebo
7.6 50 31.9 Metformin Exenatide 86 Placebo
8.1 53 33.7 Lixisenatide 323 Placebo
7.6 50.6 31.9 Metformin Exenatide 86 Placebo
9 57 33.2 Liraglutide 100 Placebo
7 62 30.5 Liraglutide 100 Placebo
6.2 51.8 34 Exenatide 110 Placebo
6.1 56 32.7 Taspoglutide 182 Placebo
7.3 59 32.8 Taspoglutide 106 Placebo
2.8 37 33.2 Taspoglutide 112 Placebo
5.2 42 36.9 Taspoglutide 149 Placebo
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2SEARCH TERMS FOR DPP-4inhibitors
"Diabetes Mellitus, Type 2/drug therapy*"[MeSH ] OR "Diabetes Mellitus, Type 
2/ethnology*"[MeSH ] OR "Diabetes Mellitus, Type 2/blood* "[MeSH ] OR "Diabetes Mellitus, 
Type 2/epidemiology"[MeSH ] OR "Metabolic Syndrome/epidemiology* "[MeSH ] OR 
"Metabolic Syndrome/therapy*"[MeSH ]
AND 
“Dipeptidyl-Peptidase IV Inhibitors/administration & dosage*”[MeSH] OR “Dipeptidyl-
Peptidase IV Inhibitors/therapeutic use*” [MeSH] OR Sitagliptin OR Linagliptin OR Alogliptin 
OR Vildagliptin OR Saxagliptin
 NOT
 “Dipeptidyl-Peptidase IV Inhibitors /adverse effects”[MeSH] OR Retinopathy OR Nephropathy 
OR Cardiovascular OR renal
Filters: Clinical Trial; Humans; Age 19+; English
SEARCH TERMS FOR SGLT-2inhibitors
"Diabetes Mellitus, Type 2/drug therapy*"[MeSH ] OR "Diabetes Mellitus, Type 
2/ethnology*"[MeSH ] OR "Diabetes Mellitus, Type 2/blood* "[MeSH ] OR "Diabetes Mellitus, 
Type 2/epidemiology"[MeSH ] OR "Metabolic Syndrome/epidemiology* "[MeSH ] OR 
"Metabolic Syndrome/therapy*"[MeSH ]
AND 
“Sodium-Glucose Transporter 2/antagonists & inhibitors*”[MeSH] OR Empagliflozin OR 
Dapagliflozin OR Luseogliflozin OR Canagliflozin OR Ipragliflozin OR Tofogliflozin
NOT
 “Sodium-Glucose Transporter 2/antagonists & inhibitors* /adverse effects”[MeSH] OR 
Retinopathy OR Nephropathy OR Cardiovascular OR Renal 
 Filters: Clinical Trial; Humans; English, Age : 19 +
SEARCH TERMS FOR GLP 1RA
“Diabetes Mellitus, Type 2/drug therapy*"[MeSH ] OR "Diabetes Mellitus, Type 
2/ethnology*"[MeSH ] OR "Diabetes Mellitus, Type 2/blood* "[MeSH ] OR "Diabetes Mellitus, 
Type 2/epidemiology"[MeSH ] OR "Metabolic Syndrome/epidemiology* "[MeSH ] OR 
"Metabolic Syndrome/therapy*"[MeSH ]
 AND 
“glucagon-like peptide-1 receptor agonists"[MeSH] OR Exenatide OR Liraglutide OR 
Lixisenatide OR Dulaglutide OR Albiglutide
NOT
“ glucagon-like peptide-1 receptor agonists /adverse effects”[MeSH] OR Retinopathy OR 
Nephropathy OR Cardiovascular OR renal
 Filters: Clinical Trial; Humans; Age 19+, English
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3DPP-4inhibitors
Figure S1a : Selection of DPP-4 inhibitor studies included in meta-analysis.





























Full-text articles assessed 
for eligibility
(n =148)
Full-text articles excluded, 
with reasons (n =122)
<70% Asian or White : 48
Study duration <24 
weeks : 34
Study duration >52 
weeks : 1
less than 50 in each 
arm : 18
No placebo comparison : 5
No efficacy measure : 13
Retracted : 1
No ethnicity info : 2






Records identified through other 
sources(ref from studies)
(n = 12)
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4Figure S1b : Risk of Bias of  DPP-4 inhibitor studies included in meta-analysis.




















Fig S1c : Funnel plot of change in HbA1c in the studies used in the meta-analysis for DPP-4 inhibitors
p=0.6554
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Heterogeneity: I2 = 94%, 2 = 0.0948, p  < 0.01







Heterogeneity: I2 = 94%, 2 = 0.0765, p  < 0.01

























































































































































































































































































































































































































Fig S1e : Forest plot for White and Asian dominant groups for DPP-4 inhibitors for 12 weeks
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6SGLT-2inhibitors
Figure S2a : Risk of Bias of SGLT-2 inhibitor studies included in meta-analysis.
























Records after putting filters Clinical Trial, Age 




Full-text articles assessed 
for eligibility
(n =86)
Full-text articles excluded, 
with reasons (n =70)
<70% Asian or White : 16
Study duration <24 
weeks : 5
Study duration >52 
weeks : 1
less than 50 in each 
arm : 7
No placebo comparison : 
28
No ethnicity info  : 7
No efficacy measure : 6
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7Figure S2b : Risk of Bias of SGLT-2 inhibitor studies included in meta-analysis.


















Fig S2c : Funnel plot of change in HbA1c in the studies used in the meta-analysis for SGLT-2 inhibitors
p=0.947
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Heterogeneity: I2 = 85%, 2 = 0.0658, p  < 0.01







Heterogeneity: I2 = 87%, 2 = 0.0704, p  < 0.01










































































































































































































































































Fig S2e : Forest plot for White and Asian dominant groups for SGLT-2 inhibitors for 12 weeks
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9GLP-1RA
Figure S3a : Selection of GLP-1RA studies included in meta-analysis.
























Records after putting filters Clinical Trial, Age 19+, 




Full-text articles assessed 
for eligibility
(n =117)
Full-text articles excluded, 
with reasons (n =95)
<70% Asian or White : 8 
Study duration <24 
weeks : 8
Study duration >52 
weeks : 1
less than 50 in each 
arm : 9
No placebo comparison : 
54
Drug Switch : 2
Insulin background : 1
No efficacy measure : 12






Records identified through other 
sources(ref from studies)
(n = 4)
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10
Figure S3b : Risk of Bias of GLP-1RA studies included in meta-analysis.


















                           
   Fig S3c : Funnel plot of change in HbA1c in the studies used in the meta-analysis for GLP-1R
  p=0.332
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Heterogeneity: I2 = 76%, 2 = 0.0381, p  < 0.01







Heterogeneity: I2 = 75%, 2 = 0.0361, p  < 0.01























































































































































































































































































































































Fig S3e : Forest plot for White and Asian dominant groups for GLP 1RA  for 12 weeks
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Author Year Adequacy of Sequence Generation Allocation concealmeant Blinding of participants and personnel Incomplete outcome data Selective reporting Other bias
Dou J 2017 Unclear Low risk Low risk Low risk Low risk Low risk
Gantz I 2017 Unclear Low risk Low risk Low risk Low risk Low risk
Wang W 2016 Unclear Unclear Low risk Low risk Low risk Low risk
Tinahones FJ 2016 Unclear Low risk Low risk Low risk Low risk Low risk
Matthaei S 2015 Low risk Low risk Low risk Low risk Low risk Low risk
Yang W 2014 Unclear Unclear Low risk Low risk Low risk Low risk
Lukashevich V 2013 Unclear Unclear Low risk Low risk Low risk Low risk
Barnett AH 2013 Low risk Low risk Low risk Low risk Low risk Low risk
Strain WD 2013 Low risk Low risk Low risk Low risk Low risk Low risk
Derosa G 2012 Low risk Low risk Low risk Low risk Low risk Low risk
Pan C 2012 Unclear Unclear Low risk Low risk Low risk Low risk
Pan CY 2011 Low risk Unclear Low risk Low risk Low risk Low risk
Yang W 2011 Low risk Unclear Low risk Low risk Low risk Low risk
Taskinen MR 2010 Unclear Unclear Low risk Low risk Low risk Low risk
Rosenstock J 2009 Unclear Unclear Low risk Low risk Low risk Low risk
DeFronzo RA 2009 Low risk Low risk Low risk Low risk Low risk Low risk
Nauck MA 2009 Low risk Low risk Low risk Low risk Low risk Low risk
Garber AJ 2007 Unclear Unclear Low risk Low risk Low risk Low risk
Bosi E 2007 Unclear Unclear Low risk Low risk Low risk Low risk
Rosenstock J 2006 Unclear Unclear Low risk Low risk Low risk Low risk
Gomis R 2011 Low risk Unclear Low risk Low risk Low risk Low risk
Yang 2012 Low risk Unclear Low risk Low risk Low risk Low risk
Bergenstal 2012 Unclear Unclear Low risk Low risk Low risk Low risk
Pratley_PG 2009 Low risk Low risk Low risk Low risk Low risk Low risk
Pratley_SU 2009 Low risk Unclear Low risk Low risk Low risk Low risk
Kadowaki 2017 Low risk Unclear Low risk Low risk Low risk Low risk
Table S1a : Risk of bias assessment for DPP-4 inhibitors for the included studies
Author Year Adequacy of Sequence Generation Allocation concealmeant Blinding of participants and personnel Incomplete outcome data Selective reporting Other bias
Han KA 2018 Low risk Low risk Low risk Low risk Low risk Low risk
Kawamori R 2018 Low risk Low risk Low risk Low risk Low risk Low risk
Kadowaki T 2017 Low risk Unclear Low risk Low risk Low risk Low risk
Mathieu C 2016 Unclear High risk Low risk Low risk Low risk Low risk
Rodbard HW 2016 Low risk Low risk Low risk Low risk Low risk Low risk
Mathieu C 2015 Low risk Low risk Low risk Low risk Low risk Low risk
Matthaei S 2015 Unclear Low risk Low risk Low risk Low risk Low risk
Kashiwagi A 2014 Unclear Unclear Low risk Low risk Low risk Low risk
Kaku K 2014 High risk Low risk Low risk Low risk Low risk Low risk
Jabbour SA 2013 Unclear Unclear Low risk Low risk Low risk Low risk
Wilding JP 2013 Low risk Low risk Low risk Low risk Low risk Low risk
Rosenstock J 2012 High risk Unclear Low risk Low risk Low risk Low risk
Inagaki N 2014 Unclear Low risk Low risk Low risk Low risk Low risk
Seino Y 2014 Low risk High risk Low risk Low risk Low risk Low risk
Bode B 2013 Low risk Low risk Low risk Low risk Low risk Low risk
Jabbour SA 2018 High risk Low risk Low risk Low risk Low risk Low risk
Table S1b : Risk of bias assessment for SGLT-2 inhibitors for the included studies
Author Year Adequacy of Sequence Generation Allocation concealmeant Blinding of participants and personnel Incomplete outcome data Selective reporting Other bias
Jabbour SA 2018 Low risk Low risk Low risk Low risk Low risk Low risk
Lingvay I 2018 Low risk Low risk Low risk Low risk Low risk Low risk
Ludvik B 2018 Unclear Low risk Low risk Low risk Low risk Low risk
Meneilly GS 2017 Unclear Low risk Low risk Low risk Low risk Low risk
Dungan KM 2016 Unclear Unclear Low risk Low risk Low risk Low risk
Nauck MA 2015 Unclear Low risk Low risk Low risk Low risk Low risk
Reusch J 2014 Low risk Low risk Low risk Low risk Low risk Low risk
Wysham C 2014 Low risk Low risk Low risk Low risk Low risk Low risk
Yu Pan C 2014 Unclear Low risk Low risk Low risk Low risk Low risk
Bolli GB 2013 Unclear Unclear Low risk Low risk Low risk Low risk
Derosa G 2013 Low risk Low risk Low risk Low risk Low risk Low risk
Pinget M 2013 Low risk Low risk Low risk Low risk Low risk Low risk
Seino Y 2012 Unclear Low risk Low risk Low risk Low risk Low risk
Derosa G 2012 Unclear Low risk Low risk Low risk Low risk Low risk
Kaku K 2010 Unclear Unclear Low risk Low risk Low risk Low risk
Zinman B 2009 Unclear Low risk Low risk Low risk Low risk Low risk
Nauck M 2008 Low risk Low risk Low risk Low risk Low risk Low risk
DeFronzo RA 2005 Unclear Unclear Low risk Low risk Low risk Low risk
Bergenstal 2012 Unclear Unclear Low risk Low risk Low risk Low risk
Henry 2012 Unclear Low risk Low risk Low risk Low risk Low risk
Raz 2012 Unclear Unclear Low risk Low risk Low risk Low risk
Hollander 2013 Low risk Low risk Low risk Low risk Low risk Low risk
Table S1c : Risk of bias assessment for GLP-1RA  for the included studies
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Ethnicity Number of studies Mean difference (95% CI)
Asian 9 -0.62[-0.80,-0.45]
White 17 -0.49[-0.59,-0.38]




Ethnicity Number of studies Mean difference (95% CI)
Asian 7 -0.96[-1.10,-0.82]
White 9 -0.64[-0.74,-0.53]




Ethnicity Number of studies Mean difference (95% CI)
Asian 3 -0.76[-1.19,-0.33]
White 20 -0.79[-0.89,-0.69]
Test for sub-group differences (p 
value)
0.8957
Table S2a : Results of sub-group analysis for DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1RA for 24 weeks
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Ethnicity Number of studies Mean difference (95% CI)
Asian 14 -0.73[-0.88,-0.57]
White 19 -0.49[-0.59,-0.39]




Ethnicity Number of studies Mean difference (95% CI)
Asian 9 -0.85[-1.03,-0.66]
White 12 -0.57[-0.69,-0.44]




Ethnicity Number of studies Mean difference (95% CI)
Asian 5 -0.79[-1.03,-0.54]
White 22 -0.79[-0.89,-0.70]
Test for sub-group differences (p 
value)
0.9657
Table S2b : Results of sub-group analysis for DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1RA for 12 weeks
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Variable Estimate SE CI p value
Intercept -0.15 0.40 [-0.93,0.64] 0.72
Age -0.01 0.01 [-0.02,0.01] 0.33
Intercept -0.63 0.08 [-0.78,-0.47] <0.01
Percentage of white 0 0 [-0.00,0.00] 0.12
Intercept -0.37 0.14 [-0.64,-0.10] <0.01
Duration of diabetes -0.03 0.02 [-0.07,0.02] 0.22
Intercept -0.38 0.29 [-0.94,0.18] 0.19
Percentage of men 0 0.01 [-0.01,0.01] 0.60
Intercept -0.97 0.5 [-1.95,-0.02] 0.05
BMI baseline 0.01 0.02 [-0.02,0.05] 0.38
Intercept -0.56 1.01 [-2.55,1.42] 0.58
HbA1c baseline 0 0.12 [-0.24,0.24] 0.98
SGLT-2 inhibitor
Variable Estimate SE CI p value
Intercept 0.34 1.27 [-2.15,2.83] 0.79
Age -0.02 0.02 [-0.06,0.02] 0.38
Intercept -0.94 0.07 [-1.08,-0.81] <0.01
Percentage of white 0 0 [0.00,0.01] <0.01
Intercept -0.74 0.26 [-1.25,-0.23] <0.01
Duration of diabetes -0.01 0.03 [-0.07,0.06] 0.85
Intercept -0.29 0.30 [-0.88,0.29] 0.33
Percentage of men -0.01 0.01 [-0.02,0] 0.10
Intercept -1.91 0.41 [-2.72,-1.09] <0.01
BMI baseline 0.04 0.01 [0.01,0.07] 0.01
Intercept -1.19 1.61 [-4.34,1.96] 0.46
HbA1c baseline 0.05 0.20 [-0.33,0.43] 0.80
GLP-1RA inhibitor
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Variable Estimate SE CI p value
Intercept -0.80 0.67 [-2.12,0.52] 0.23
Age 0 0.01 [-0.02,0.02] 0.98
Intercept -0.78 0.14 [-1.05,-0.51] <0.01
Percentage of white 0 0 [0,0] 0.99
Intercept -0.68 0.40 [-1.78,-0.22] <0.01
Duration of diabetes -0.01 0.01 [-0.01,0.02] 0.59
Intercept -1.00 0.38 [-1.81,-0.32] <0.01
Percentage of men 0.01 0.01 [-0.01,0.02] 0.43
Intercept -0.83 0.60 [-2.00,0.34] 0.17
BMI baseline 0 0.02 [-0.04,0.04] 0.94
Intercept -0.80 1.16 [-3.08,1.48] 0.49
HbA1c baseline 0 0.14 [-0.28,0.28] 0.99
Table S3: Univariate meta-regression analysis.
Drug Ethnicity Monotherapy Dual therapy Triple therapy Total
DPP-4i Asian 3 4 1 8
Percent(%) 37.5 50 12.5
White 6 10 2 18
Percent(%) 33.3 55.5 11.1
SGLT 2i Asian 5 2 0 7
Percent(%) 71.4 28.6 -
White 6 1 2 9
Percent(%) 66.6 11.1 22.2
GLP 1RA Asian 3 - - 3
Percent(%) 100 - -
White 17 3 - 20
Percent(%) 85 15 -
Table S4: Percentage of Asian or White studies in multiple therapy
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